Androgen Antagonists

"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds which inhibit or antagonize the biosynthesis or actions of androgens.

Descriptor ID	D000726
MeSH Number(s)	D06.347.065 D27.505.696.399.450.065
Concept/Terms	Androgen Antagonists Androgen Antagonists Antagonists, Androgen Antiandrogens Anti-Androgen Effect Anti-Androgen Effect Anti Androgen Effect Effect, Anti-Androgen Antiandrogen Effect Effect, Antiandrogen Antiandrogen Effects Effects, Antiandrogen Anti-Androgen Effects Anti Androgen Effects Effects, Anti-Androgen

Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Androgen Antagonists [D06.347.065]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Androgen Antagonists [D27.505.696.399.450.065]

Below are MeSH descriptors whose meaning is related to "Androgen Antagonists".

Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.

Bar chart showing 40 publications over 15 distinct years, with a maximum of 8 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2003	2	2	4
2004	0	1	1
2006	1	0	1
2007	5	1	6
2008	0	2	2
2009	1	1	2
2010	1	3	4
2011	6	2	8
2012	1	2	3
2013	4	0	4
2017	1	0	1
2020	1	0	1
2021	0	1	1
2022	0	1	1

Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.

Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, Wefel JS, Martin AG, Michalski JM, Angyalfi SJ, Lukka H, Faria SL, Rodrigues GB, Beauchemin MC, Lee RJ, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sartor O, Feng F, Sandler HM. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022 05 14; 399(10338):1886-1901.

View in: PubMed
Schiewer MJ, Knudsen KE. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness. Urol Clin North Am. 2021 Aug; 48(3):339-347.

View in: PubMed
Gomella LG. COVID-19 and The Prostate Cancer Connection. Can J Urol. 2020 10; 27(5):10346.

View in: PubMed
Bernard B, Muralidhar V, Chen YH, Sridhar SS, Mitchell EP, Pettaway CA, Carducci MA, Nguyen PL, Sweeney CJ. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer. Cancer. 2017 May 01; 123(9):1536-1544.

View in: PubMed
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37.

View in: PubMed
Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43.

View in: PubMed
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38.

View in: PubMed
Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab. 2013 May; 98(5):E820-8.

View in: PubMed
Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI. Contemporary grading for prostate cancer: implications for patient care. Eur Urol. 2013 May; 63(5):892-901.

View in: PubMed
Cheng HH, Lin DW, Yu EY. Advanced clinical states in prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):561-71.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement